Evidence map›Paper›PMID 41684541›Full record

ArticleFrontiers in immunology2025

B-cell epitope mapping and characterization of antibody responses to recombinant PvRipr in malaria-exposed individuals.

Isabela Ferreira Soares, Cinthia Magalhães Rodolphi, Ana Luiza Carneiro Alencar, Ada da Silva Matos, Rodrigo Nunes Rodrigues-da-Silva, Barbara de Oliveira Baptista, Rodrigo Medeiros Martorano, Hugo Amorim Dos Santos de Souza, Evelyn Kety Pratt Riccio, Jenifer Peixoto de Barros and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Isabela Ferreira SoaresLaboratório de Imunoparasitologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
Cinthia Magalhães RodolphiLaboratório de Imunoparasitologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
Ana Luiza Carneiro AlencarLaboratório de Imunoparasitologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
Ada da Silva MatosLaboratório de Imunoparasitologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
Rodrigo Nunes Rodrigues-da-SilvaLaboratório de Hantaviroses e Rickettsioses, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
Barbara de Oliveira BaptistaLaboratório de Pesquisa em Malária, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
Rodrigo Medeiros MartoranoLaboratório de Doenças infecciosas na Amazônia Ocidental, Universidade Federal do Acre (UFAC), Cruzeiro do Sul, AC, Brazil.
Hugo Amorim Dos Santos de SouzaLaboratório de Pesquisa em Malária, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
Evelyn Kety Pratt RiccioLaboratório de Pesquisa em Malária, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
Jenifer Peixoto de BarrosLaboratório de Pesquisa em Malária, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
Paulo Renato Rivas TotinoLaboratório de Pesquisa em Malária, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
Cláudio Tadeu Daniel-RibeiroLaboratório de Pesquisa em Malária, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
Lilian Rose Pratt-RiccioLaboratório de Pesquisa em Malária, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
Josué da Costa Lima-JuniorLaboratório de Imunoparasitologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Malaria caused by Methods: ELISA assays were performed using plasma samples from individuals naturally exposed to malaria in the Brazilian Amazon in order to determine levels of IgM, IgG and IgG subclasses against PvRipr. In addition, linear B-cell epitopes within the protein were identified. Results and Discussion: Our results demonstrated that PvRipr is naturally immunogenic, as more than 60% of the individuals presented IgM or IgG antibodies against recombinant PvRipr. The profile of IgG subclasses was also investigated and higher frequencies of seropositive individuals for IgG1 and IgG2 were observed. After

Indexed as

Antibodies, ProtozoanAntigens, ProtozoanEpitope MappingEpitopes, B-LymphocyteMalaria, VivaxPlasmodium vivaxProtozoan ProteinsAdolescentAdultAntibody FormationBrazilFemaleHumansImmunoglobulin GImmunoglobulin MMalaria VaccinesAntibodies, ProtozoanAntigens, ProtozoanEpitopes, B-LymphocyteImmunoglobulin GImmunoglobulin MMalaria VaccinesProtozoan ProteinsRecombinant ProteinsB-cell epitopesmalariaP. vivaxRiprvaccine candidate

Identifiers

PMID41684541
PMCPMC12891138

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.